CGEM · Cullinan Therapeutics, Inc.
$17.21
-0.26 (-1.49%)
At close · Jul 29
Market Cap
$1.07B
Shares
61.46M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.21
Open$17.65
Day$16.62–17.98
52W$5.68–19.43
Avg vol 30d942K
Short int10.3M · 16.7% float · 15.2d
Short vol73%
DataJan 2021–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+6%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
84%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+40%
trailing
YTD return
+66%
this year
Relative strength
+33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow
Distributing
27 of 173 funds reported for Jun 30 · net -42.1K sh shares · +3 new
Insider flow
Distributing
Net -$117.0K over 90 days · 100% sells
Short interest
Falling
16.74% of float · ▼ -2.9% MoM · 15.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−255%
Y/Y
Free cash flow
$-175.8M
Balance sheet
$88.3M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+6%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
84%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $16 › 200d $13 — 50d above 200d
Institutional flow
Distributing
27 of 173 funds reported for Jun 30 · net -42.1K sh shares · +3 new
Insider flow
Distributing
Net -$117.0K over 90 days · 100% sells
Short interest
Falling
16.74% of float · ▼ -2.9% MoM · 15.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
173 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $17 · 84%
52-wk high $19
vs 200-day avg +33%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGEM
this stock
Cullinan Therapeutics, Inc.
|
$1.07B | +66.3% | -100.0% | — | 16.7% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGEM | -2.5% | -5.5% | +39.6% | -5.5% | +66.3% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -0.1% | -3.2% | +33.3% | -3.2% | +59.3% |
Key facts
CIK
1789972
CUSIP
230031106
13F (30d)
26 filings
26 filers
Visit website
Investor relations